In a series of phase 2b trials, berobenatide, an investigational injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA), demonstrated robust weight loss, both in people with obesity or overweight, and in those with obesity or overweight and type 2 diabetes
Janki Shah, PharmD, BCACP, BC-ADM has no relationships with ineligible companies and therefore have nothing to disclose
Interestingly, Some People Alternate A subset of people experience alternating constipation and diarrhea
Despite the preference of type I fibers for fatty acid oxidation, the skeletal muscle cells in these fibers possess the highest levels of the insulin receptor
The ketogenic group preserved fat-free mass significantly better than the low-calorie group
See our Privacy Policy on our contact page for more information